公开(公告)号：US20240052387A1

公开(公告)日：2024-02-15

申请号：US17766552

申请日：2020-10-08

Applicant: JOHANN WOKFGANG GOETHE-UNIVERSITAT FRANKFURT AM MAIN ,  ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE

Inventor： SIMON HARTH ,  MISLAV OREB ,  JUN-YONG CHOE

IPC: C12P17/06 ,  C12P7/58 ,  C12N9/04 ,  C12N15/81

CPC classification number: C12P17/06 ,  C12P7/58 ,  C12N9/0006 ,  C12Y101/01067 ,  C12Y101/01 ,  C12N15/81 ,  C12N2800/102

Abstract: The present invention relates to polypeptides which are galacturonate (GalA) reductase variants comprising at least one amino acid substitution at a position corresponding to K261 and/or R267. The present invention further relates to nucleic acid molecules encoding the polypeptides and to host cells containing said nucleic acid molecules. The present invention further relates to a method for the production of L-galactonate (GalOA) and/or other bio-based compounds, comprising the expression of said nucleic acid molecules, preferably in said host cells. The present invention also relates to the use of the polypeptides, nucleic acids molecule or host cells for the production of L-galactonate (GalOA) and/or other bio-based compounds, and/or for the recombinant fermentation of biomaterial containing D-galacturonate (GalA).

公开(公告)号：US10729370B2

公开(公告)日：2020-08-04

申请号：US14964690

申请日：2015-12-10

Applicant: Rosalind Franklin University of Medicine and Science

Inventor： Fang Lin ,  Sai V. Yalla

IPC: A61B5/00 ,  A61B3/113 ,  A61B5/11

Abstract: The present disclosure provides a system including one or more sensors, a mounting system configured to removeably mount a computing device such that a camera of the computing device is positioned facing an eye of a subject, and a control system. The control system is configured to (a) receive sensor data from the one or more sensors, (b) determine whether the sensor data is indicative of balance instability of the subject, (c) track a position of the eye of the subject to assess vestibular dysfunction, (d) determine whether the camera data is indicative of vestibular dysfunction of the subject, and (e) in response to (i) the sensor data being indicative of balance instability of the subject and/or (ii) the camera data being indicative of vestibular dysfunction of the subject, display an indication of symptoms that are characteristic of a traumatic brain injury or concussion.

公开(公告)号：US20170268000A1

公开(公告)日：2017-09-21

申请号：US15039188

申请日：2014-12-02

Applicant: IONIS PHARMACEUTICALS ,INC. ,  ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE

Inventor： Frank RIGO ,  Michelle L. HASTINGS

IPC: C12N15/113

CPC classification number: C12N15/113 ,  A61K31/7088 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/322 ,  C12N2310/3231 ,  C12N2310/3233 ,  C12N2310/3341 ,  C12N2310/3525

Abstract: The present invention provides compounds comprising oligonucleotides complementary to a CLN3 transcript. Certain such compounds are useful for hybridizing to a CLN3 transcript, including but not limited to a CLN3 transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the CLN3 transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Batten Disease.

公开(公告)号：US20170137826A1

公开(公告)日：2017-05-18

申请号：US15349840

申请日：2016-11-11

Applicant: Rosalind Franklin University of Medicine and Science ,  The McLean Hospital Corporation

Inventor： Michelle L. Hastings ,  Ole Isacson ,  Joanna A. Korecka-Roet

IPC: C12N15/113

CPC classification number: C12N15/1137 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/3231 ,  C12N2310/3233 ,  C12N2310/346 ,  C12N2320/33 ,  C12Y207/11001 ,  C12N2310/321 ,  C12N2310/3521 ,  C12N2310/3525 ,  C12N2310/322 ,  C12N2310/3533

Abstract: The present disclosure relates generally to compounds comprising oligonucleotides complementary to a Leucine-Rich-Repeat-Kinase (LRRK2) RNA transcript. Certain such compounds are useful for hybridizing to a LRRK2 RNA transcript, including but not limited to a LRRK2 RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the LRRK2 transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Parkinson's disease.

公开(公告)号：US09102645B2

公开(公告)日：2015-08-11

申请号：US14213614

申请日：2014-03-14

Applicant: Rosalind Franklin University of Medicine and Science

Inventor： Grace E. Stutzmann ,  Russell Dahl ,  Christopher H. Kaiho

IPC: A61K31/4427 ,  A61K31/341 ,  A61K31/4166 ,  C07D307/52 ,  C07D405/12 ,  C07D307/54 ,  C07D407/12

CPC classification number: C07D307/52 ,  A61K31/341 ,  A61K31/4166 ,  A61K31/4427 ,  C07D307/54 ,  C07D405/12 ,  C07D407/12

Abstract: Disclosed herein are methods and compositions comprising compounds capable of normalizing neuronal calcium dyshomeostasis. Also disclosed are methods comprising these compounds for treating neuronal or neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, fronto-temporal dementia, Pick's disease, chronic traumatic encepholopathy, traumatic brain injury, stroke, cerebellar ataxia, multiple sclerosis, Down syndrome, and aging-related CNS disorders.

Abstract translation: 本文公开了包含能够使神经元钙发育不稳定性归一化的化合物的方法和组合物。 还公开了包括这些化合物用于治疗神经元或神经障碍的方法，包括阿尔茨海默病，帕金森病，亨廷顿舞蹈病，颞叶性痴呆，皮克病，慢性创伤性脑病，创伤性脑损伤，中风，小脑共济失调，多发性硬化症，唐氏综合征 ，和老化相关的中枢神经系统疾病。

公开(公告)号：US20140154685A1

公开(公告)日：2014-06-05

申请号：US13692477

申请日：2012-12-03

Applicant: Rosalind Franklin University Of Medicine And Science

Inventor： Dominik M. DUELLI

IPC: C12Q1/68

CPC classification number: C12Q1/6806 ,  C12Q2525/207 ,  C12Q2527/125 ,  C12Q2527/137

Abstract: The present invention provides a kit for measuring the content of micro-RNA in a human blood sample including a blood collection tube containing at least 1 μg NaF and 0.8 μg KOx; and providing a set of instructions for collecting a human blood sample in the blood collection tube.

Abstract translation: 本发明提供了一种用于测量人血液样品中微RNA含量的试剂盒，其包括含有至少1μgNaF和0.8μgKOx的采血管; 以及提供用于在采血管中收集人血液样本的一组说明书。

公开(公告)号：US20230304041A1

公开(公告)日：2023-09-28

申请号：US18188932

申请日：2023-03-23

Applicant: Rosalind Franklin University of Medicine & Science

Inventor： Johnny HE ,  Ying LIU

IPC: C12N15/86 ,  C12Q1/70

CPC classification number: C12N15/86 ,  C12Q1/701 ,  C12Q2600/136 ,  C12Q2600/158 ,  C12N2770/20043

Abstract: The present disclosure provides constructs and kits comprising SARS-CoV-2 (SARS2) replicons and methods for screening and/or evaluating anti-SARS2 drugs using the replicons.

公开(公告)号：US11732260B2

公开(公告)日：2023-08-22

申请号：US16977649

申请日：2019-03-01

Applicant: Ionis Pharmaceuticals, Inc. ,  Rosalind Franklin University of Medicine and Science

Inventor： Frank Rigo ,  Michelle L. Hastings

IPC: C07H21/04 ,  C12N15/113

CPC classification number: C12N15/113 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/32 ,  C12N2310/3231 ,  C12N2310/3233 ,  C12N2310/346 ,  C12N2320/33

Abstract: Certain embodiments disclosed herein are directed to compounds and methods for modulating APP expression. In certain embodiments, modulating the splicing of amyloid precursor protein (APP) reduces amyloid β (Aβ) production.

公开(公告)号：US11559231B2

公开(公告)日：2023-01-24

申请号：US16414951

申请日：2019-05-17

Applicant: Rosalind Franklin University of Medicine and Science

Inventor： Joanna Dabrowska

IPC: A61B5/16 ,  A61B5/00 ,  A61B5/145 ,  A61K38/095 ,  A61K9/00 ,  A61P25/22

Abstract: A method and system is provided for determining a discrimination index in a subject that may be suffering from or at risk for a stress-induced psychiatric disorder. The discrimination index may be equal to a ratio of a subject's cued fear response and non-cued fear response measured during a fear-potentiated startle (FPS) paradigm. Such a value may allow a physician or researcher to quantify how well a subject discriminates between signaled (cued) fear and un-signaled (non-cued) fear, which may be a biomarker for psychiatric disorders like post-traumatic stress disorder, panic disorder, phobias, and/or generalized anxiety disorder. The determined discrimination index may provide a standardized way of diagnosing and evaluating mental illnesses, more uniform treatment of patients, and/or more precise monitoring and evaluation of treatment efficacy.

公开(公告)号：US20220280545A1

公开(公告)日：2022-09-08

申请号：US17274981

申请日：2019-09-10

Applicant: Ionis Pharmaceuticals, Inc. ,  Rosalind Franklin University of Medicine & Science

Inventor： Michelle L. Hastings ,  Frank Rigo

IPC: A61K31/712 ,  A61K31/7125 ,  A61K31/713 ,  A61K47/02

Abstract: Provided are compounds, methods, and pharmaceutical compositions for modulating the expression of CLN3 RNA in a cell or animal, and in certain instances modulating the expression of CLN3 protein in a cell or animal Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodegenerative disease. Such N symptoms and hallmarks include poor motor function, seizures, vision loss, poor cognitive function, psychiatric problems, accumulation of autofluorescent ceroid lipopigment, brain tissue dysfunction or cell death, accumulation of mitochondrial ATP synthase subunit C, accumulation of lipofuscin, or astrocyte activation in brain tissue.